{"doi":"10.1111/ijpo.13105","title":"Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with <scp>GLP‐1RA</scp> therapy in adolescents with severe obesity","abstract":"INTRODUCTION: Whilst glucagon-like peptide-1 receptor agonists (GLP1-RAs) are effective for treating adolescent obesity, weight loss maintenance (WLM; preventing weight regain) remains a challenge. Our goal was to investigate appetite/satiety hormones and eating behaviours that may predict WLM with exenatide (a GLP1-RA) versus placebo in adolescents with severe obesity. METHODS: Adolescents who had ≥5% body mass index (BMI) reduction with meal replacement therapy were randomized to 52 weeks of once-weekly exenatide extended release or placebo. In this secondary analysis, eating behaviours and appetite/satiety regulation hormones post-meal replacement therapy (pre-randomization to exenatide or placebo) were evaluated as possible predictors of WLM. Percent change in BMI from randomization to 52 weeks served as the primary measure of WLM. RESULTS: The analysis included 66 adolescents (mean age 16.0 years; 47% female). Lower leptin response to meal testing was associated with greater WLM in terms of BMI percent change in those receiving exenatide compared to placebo (p = 0.007) after adjusting for sex, age and BMI. There were no other significant predictors of WLM. CONCLUSIONS: Prior to exenatide, lower leptin response to meals was associated with improved WLM with exenatide compared to placebo. The mostly null findings of this study suggest that GLP1-RA treatment may produce similar WLM for adolescents with obesity regardless of age, BMI, sex and eating behaviours.","journal":"Pediatric Obesity","year":2024,"id":436172,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9592,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":245454,"name":"Aaron S. Kelly","orcid":"0000-0001-8530-107X","position":1,"is_corresponding":false},{"id":928980,"name":"Alicia Kunin‐Batson","orcid":"0000-0002-7607-5602","position":2,"is_corresponding":false},{"id":973192,"name":"Claudia K. Fox","orcid":"0000-0001-5732-0062","position":3,"is_corresponding":false},{"id":288655,"name":"Rebecca Freese","orcid":"0000-0001-9477-4231","position":4,"is_corresponding":false},{"id":832867,"name":"Justin Clark","orcid":"0000-0003-0133-1613","position":5,"is_corresponding":false},{"id":422113,"name":"Kyle Rudser","orcid":"0000-0001-9968-0090","position":6,"is_corresponding":false},{"id":392704,"name":"Eric M. Bomberg","orcid":"0000-0002-8037-4314","position":7,"is_corresponding":false},{"id":376314,"name":"Justin R. Ryder","orcid":"0000-0002-7506-9497","position":8,"is_corresponding":false},{"id":539609,"name":"Amy C. Gross","orcid":"0000-0003-2809-8460","position":9,"is_corresponding":false},{"id":802604,"name":"Megan O. Bensignor","orcid":"0000-0002-9341-1858","position":0,"is_corresponding":true}],"reference_count":39,"raw_metadata":null,"created_at":"2026-07-19T02:00:12.706156Z","pmid":"38339799","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}